Health
RFK Jr. appoints Robert Malone, Martin Kulldorff, other COVID shot critics to overhauled CDC vaccine panel
From LifeSiteNews
By Robert Jones
Health and Human Services Secretary Robert F. Kennedy Jr. has announced eight appointments for the CDC’s top vaccine advisory panel, following his dismissal of all 17 previous members, citing a need to rebuild public trust in the federal immunization process.
On Monday, I took a major step towards restoring public trust in vaccines by reconstituting the Advisory Committee for Immunization Practices (ACIP). I retired the 17 current members of the committee. I’m now repopulating ACIP with the eight new members who will attend ACIP’s…
— Secretary Kennedy (@SecKennedy) June 11, 2025
RFK Jr. said the new Advisory Committee on Immunization Practices (ACIP) will demand “definitive safety and efficacy data” before issuing any new vaccine recommendations and will re-evaluate existing guidance. The restructured panel is set to convene on June 25.
The appointees include several prominent physicians and scientists, including former Harvard epidemiologist Martin Kulldorff and mRNA researcher Robert Malone, both known for their criticism of COVID-19-era public health policy and the COVID-19 shots.
Kulldorff helped draft the Great Barrington Declaration with Jay Bhattacharya and Sunetra Gupta, which called for focused protection rather than mass lockdowns – a position widely debated among epidemiologists. He also spoke out strongly against vaccine passports and mandates, as well as mask mandates and contact tracing. He was dismissed from Harvard in 2024 because of his refusal to receive the COVID-19 injections.
Malone, who conducted early work on mRNA vaccine delivery systems, was banned from several platforms for posts deemed “misleading” during the COVID crisis. He has given related interviews on The Joe Rogan Experience and elsewhere and was reinstated on X following Elon Musk’s revision of COVID-19 policies.
Retsef Levi, a professor at MIT, has raised concerns about potential cardiovascular risks linked to COVID-19 mRNA shots and has called for stricter safety monitoring. In 2023, a petition circulated opposing his work, though it did not gain traction.
Other appointees include:
- Joseph Hibbeln, an NIH psychiatrist and nutrition researcher focused on immune and neurodevelopmental health.
- Cody Meissner, a pediatric infectious disease expert with previous experience on both FDA and CDC vaccine panels.
- James Pagano, a veteran emergency physician with decades of clinical experience.
- Vicky Pebsworth, a nurse-scientist with prior FDA vaccine advisory roles and Pacific Region Director of the National Association of Catholic Nurses. She is also a Lay Dominican.
- Michael Ross, an OB-GYN and clinical researcher with a background in immunology and women’s health policy.
Joseph R. Hibbeln, MD, is a psychiatrist and neuroscientist with a career in clinical research, public health policy, and federal service. As former Acting Chief of the Section on Nutritional Neurosciences at the National Institutes of Health, he led research on immune regulation, neurodevelopment, and mental health. His work has informed U.S. public health guidelines, particularly in maternal and child health. With more than 120 peer-reviewed publications and extensive experience in federal advisory roles, Dr. Hibbeln brings expertise in immune-related outcomes, psychiatric conditions, and evidence-based public health strategies.
Martin Kulldorff, MD, PhD, is a biostatistician and epidemiologist formerly at Harvard Medical School and a leading expert in vaccine safety and infectious disease surveillance. He has served on the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee and the CDC’s Vaccine Safety Subgroup of the Advisory Committee on Immunization Practices, where he contributed to national vaccine safety monitoring systems. Dr. Kulldorff developed widely used tools such as SaTScan and TreeScan for detecting disease outbreaks and vaccine adverse events. His expertise includes statistical methods for public health surveillance, immunization safety, and infectious disease epidemiology. He has also been an influential voice in public health policy, advocating for evidence-based approaches to pandemic response.
Retsef Levi, PhD, is the Professor of Operations Management at the MIT Sloan School of Management and a leading expert in healthcare analytics, risk management, and vaccine safety. He has served as Faculty Director of MIT Sloan’s Food Supply Chain Analytics and Sensing Initiative and co-led the Leaders for Global Operations Program. Dr. Levi has collaborated with public health agencies to evaluate vaccine safety, including co-authoring studies on mRNA COVID-19 vaccines and their association with cardiovascular risks. His research has contributed to discussions on vaccine manufacturing processes, safety surveillance, and public health policy. Dr. Levi has also served on advisory committees and engaged in policy discussions concerning vaccine safety and efficacy. His expertise spans healthcare systems optimization, epidemiologic modeling, and the application of AI and data science in public health. Dr. Levi’s work continues to inform national and international debates on immunization safety and health system resilience.
Robert W. Malone, MD, is a physician-scientist and biochemist known for his early contributions to mRNA vaccine technology. He conducted foundational research in the late 1980s on lipid-mediated mRNA delivery, which laid the groundwork for later developments in mRNA-based therapeutics. Dr. Malone has held academic positions at institutions including the University of California, Davis, and the University of Maryland, and has served in advisory roles for the U.S. Department of Health and Human Services and the Department of Defense. His expertise spans molecular biology, immunology, and vaccine development.
Cody Meissner, MD, is a Professor of Pediatrics at the Geisel School of Medicine at Dartmouth and a nationally recognized expert in pediatric infectious diseases and vaccine policy. He has served as Section Chief of Pediatric Infectious Disease at Dartmouth-Hitchcock Medical Center and has held advisory roles with both the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). Dr. Meissner has been a voting member of the CDC’s Advisory Committee on Immunization Practices and the FDA’s Vaccines and Related Biological Products Advisory Committee, where he has contributed to national immunization guidelines and regulatory decisions. His expertise spans vaccine development, immunization safety, and pediatric infectious disease epidemiology. Dr. Meissner has also been a contributing author to American Academy of Pediatrics policy statements and immunization schedules, helping shape national standards for pediatric care.
James Pagano, MD, is a board-certified Emergency Medicine physician with over 40 years of clinical experience following his residency at UCLA. He has worked in diverse emergency settings, from Level 1 trauma centers to small community hospitals, caring for patients across all age groups, including infants, pregnant women, and the elderly. Dr. Pagono served on multiple hospital committees, including utilization review, critical care, and medical executive boards. He is strong advocate for evidence-based medicine.
Vicky Pebsworth, OP, PhD, RN, earned a doctorate in public health and nursing from the University of Michigan. She has worked in the healthcare field for more than 45 years, serving in various capacities, including critical care nurse, healthcare administrator, health policy analyst, and research scientist with a focus on public health policy, bioethics, and vaccine safety. She is the Pacific Region Director of the National Association of Catholic Nurses. She is a former member of the Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee’s 2009 H1N1 Vaccine Safety Risk Assessment Working Group and Vaccine Safety Working Group (Epidemiology and Implementation Subcommittees).
Michael A. Ross, MD, is a Clinical Professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy. He has served on the CDC’s Advisory Committee for the Prevention of Breast and Cervical Cancer, where he contributed to national strategies for cancer prevention and early detection, including those involving HPV immunization. With research experience in hormone therapies, antibiotic trials, and immune-related conditions such as breast cancer prevention, Dr. Ross has engaged in clinical investigations with immunologic relevance. He has advised major professional organizations, including the American College of Obstetricians and Gynecologists, and contributed to federal advocacy efforts around women’s health and preventive care. His continued service on biotech and healthcare boards reflects his commitment to advancing innovation in immunology, reproductive medicine, and public health.
Kennedy framed the move as part of a broader campaign to remove conflicts of interest and restore credibility to federal vaccine recommendations. Just a few days ago, he accused the panel of having been “little more than a rubber stamp for any vaccine” and pledged that the new members would not have direct ties with the vaccine industry.
The new ACIP, he said, will be focused on what RFK called “gold-standard science” and “common sense.” The June meeting will mark the beginning of its work.
Health
Lack of adequate health care pushing Canadians toward assisted suicide
From LifeSiteNews
The family of an elderly man is speaking out about the terrible hospital conditions that led their father to request euthanasia before he died of natural causes.
The family of Cleo Gratton, an 84-year-old retired diamond driller who died earlier this month in Chelmsford, Ontario, of natural causes after being approved for assisted suicide, is speaking publicly about their appalling experience in the Canadian healthcare system.
According to the CBC, the elderly man “told his family he would rather die than go back to Health Sciences North in Sudbury,” and that a recent stay there found Gratton, who was suffering from heart disease and kidney failure, spending one night in the emergency room and then being transferred to a bed sitting in the hallway on the seventh floor.
“There were no lights, all the bulbs in that hallway had been completely removed,” his daughter, Lynn, told the CBC. “The only light we had was almost like a desk lamp that had been bolted to the wall. Patients are passing by, nurses are going by, no privacy, no compassion, no dignity.” The visit took place in mid-October, after which Gratton decided to apply for “medical aid in dying,” or assisted suicide.
Lynn said that nurses had to use headlamps to inspect her father’s feet, and that the experience was “just one thing after another and it really opened our eyes to what’s going on in our hospitals. My dad said, ‘Push, push, push for change. Make people aware of what’s gong on. Open the discussion, bring it to your MP, your MPP, keep going straight up.”
His family is now honoring his wishes to speak out about his experience. The doctors and nurses, Lynn emphasized, were “amazing,” but she noted that they seem overworked. “Why are they still taking in patients if we have an overcrowding issue and they have no place to put these people?” she said.
Cleo Gratton, who died of natural causes surrounded by his family before he could go through with assisted suicide, is just the most recent of many examples of Canadians opting for assisted suicide because they could not access the care that they actually desired.
In Quebec last year, Norman Meunier, a quadriplegic man, developed bedsores after four days left on an ER stretcher without a good mattress. That experience combined with lack of available homecare pushed him to request, and receive, assisted suicide.
An unnamed woman in her 80s, referred to in a MAID report as “Mrs. B,” received MAID earlier this year after requesting but being denied palliative or hospice care. Instead, with her spouse burning out as the result of her care, a rushed MAID assessment was completed, and she died by lethal injection.
In 2022, 44-year-old Winnipeg woman Sathya Dhara Khovac died by euthanasia after failing to receive the homecare resources she had desperately sought. In her posthumous obituary, she said she could have had more time if she’d had more help.
In 2019, 41-year-old Sean Tagert was euthanized after spending years attempting to find and fund the homecare and resources he needed to stay in the community where his son lived. He did not want to die but felt that he had no other choice.
And, among other stories, at least four Canadian veterans were offered assisted suicide in lieu of the unavailable mental health supports they were requesting.
Stories of Canadians seeking palliative care, mental health resources, homecare, and other medical support finding that the only option available to them is assisted suicide have become routine over the past several years. Euthanasia has become a pressure valve for an overworked and under-funded healthcare system serving an aging population increasingly need of complex care — and if assisted suicide for mental illness is legalize, things will get much, much worse.
Dr John Campbell
Cures for Cancer? A new study shows incredible results from cheap generic drug Fenbendazole
From Dr. John Campbell
You won’t hear much about Fenbendazole from the regular pipeline of medical information. There could be many reasons for that. For one, it’s primarily known for it’s use in veterinary medicine. Somehow during COVID the medical information pipeline convinced millions that if a drug is used on horses or other animals it couldn’t work for humans. Not sure how they got away with that one considering the use of animal trials for much of modern medical history.
Another possible reason, one that makes at least as much sense, is that there’s no business case for Fenbendazole. It’s been around for decades and its patent expired in the early 1990’s. That means it’s considered a generic drug that a pharmaceutical company from India could (and does) produce in mass quantities for very little profit (compared to non-generics).
So Fenbendazole is an inexpensive, widely accessible antiparasitic drug used in veterinary medicine. During the COVID pandemic a number of doctors, desperate for a suitable treatment, tried it with reportedly great levels of success. Over some time they discovered it might be useful elsewhere. Some doctors are using Fenbendazole to help treat late stage cancer. Often this is prescribed when the regular treatments clearly aren’t working and cancer is approaching or has already been declared stage 4.
What they’ve found at least in some cases is astounding results. This has resulted in a new study which medical researcher Dr. John Campbell shares in this video.
-
Daily Caller2 days agoLaura Ingraham Presses Trump On Allowing Flood Of Chinese Students Into US
-
Crime21 hours agoCBSA Bust Uncovers Mexican Cartel Network in Montreal High-Rise, Moving Hundreds Across Canada-U.S. Border
-
Environment22 hours agoThe Myths We’re Told About Climate Change | Michael Shellenberger
-
Energy1 day agoIt should not take a crisis for Canada to develop the resources that make people and communities thrive.
-
Dr John Campbell1 day agoCures for Cancer? A new study shows incredible results from cheap generic drug Fenbendazole
-
Alberta2 days agoFederal budget: It’s not easy being green
-
Business2 days agoWill Paramount turn the tide of legacy media and entertainment?
-
Artificial Intelligence20 hours agoAI Faces Energy Problem With Only One Solution, Oil and Gas




